Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT00484484

Organisation Name: Assistance Publique - Hôpitaux de Paris

Overal Status: Completed

Start Date: May 2007

Last Update: May 4, 2011

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary: Long-term opioid therapy is commonly administered for the management of severe cancer pain. Increasing doses of opioids are titrated against effects until analgesia is achieved or intolerable adverse effects occur. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been reported to improve analgesia in patients with uncontrolled pain receiving high doses of opioids. This study aims at determining the effectiveness of ketamine as an adjuvant to opioids in relieving cancer pain.

Conditions:
  • Pain


Total execution time in seconds: 0.15051913261414